The pharmacogenomic assessment of molecular epithelial-mesenchymal transition signatures reveals drug susceptibilities in cancer cell lines
Ohnmacht, A. J.; Avar, G.; Schübel, M. K.; O'Neill, T. J.; Krappmann, D.; Menden, M. P.
Show abstract
The epithelial-mesenchymal transition (EMT) is characterised by the loss of cell-cell adhesion and cell polarity, which is often exploited by cancer cells to adopt a motile, invasive and metastatic phenotype. Whilst EMT is often linked with cancer progression and therapy resistance, strategies for its selective targeting remain limited. In order to address this, we infer EMT states of cancer cell lines from their molecular signatures and use predictive and causal modelling to estimate the effect of EMT on drug susceptibility in high-throughput drug screens. For example, we show that EMT signatures in melanoma cells can predict favourable responses to the HSP90 inhibitor luminespib and demonstrate that epithelial-like melanoma cells can be sensitised to luminespib upon stimulation of EMT by TGF-{beta}. Thus, we provide an analysis that systematically yields a set of potent drugs by exploiting vulnerabilities of cancer cells undergoing EMT, which may pave the way for therapies to target these cells.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Single-cell transcriptomes identify patient-tailored therapies for selective co-inhibition of cancer clones 96%
- XENTURION, a multidimensional resource of xenografts and tumoroids from metastatic colorectal cancer patients for population-level translational oncology 96%
- The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma. 96%
Similar papers in this journal
- Non-oncology drugs are a source of previously unappreciated anti-cancer activity 95%
- Additivity predicts the efficacy of most approved combination therapies for advanced cancer 95%
- Combined KRASG12C and SOS1 inhibition enhances and extends the anti-tumor response in KRASG12C-driven cancers by addressing intrinsic and acquired resistance 95%
Similar papers in this journal
Similar papers in this journal
- Coordinated protein modules define DNA damage responses to carboplatin at single cell resolution in human ovarian carcinoma models 95%
- Functional diagnostics using fresh uncultured lung tumor cells to guide personalized treatments 94%
- Enhancer profiling identifies epigenetic markers of endocrine resistance and reveals therapeutic options for metastatic castration-resistant prostate cancer patients 94%
Similar papers in this journal
- Sequential ATR and PARP Inhibition Overcomes Acquired DNA Damaging Agent Resistance in Pancreatic Ductal Adenocarcinoma 94%
- Bypassing cisplatin resistance in Nrf2 hyperactivated head and neck cancer through effective PI3Kinase targeting 92%
- Peroxisomal β-oxidation enzyme, DECR2, regulates lipid metabolism and promotes treatment resistance in advanced prostate cancer 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.